You are here: vision-research.eu » News » Newsdetails:

Green light for EYLEA

NICE gives EYLEA a provisional green light to treat patients with visual impairment due to diabetic macular oedema

Bayer HealthCare is pleased that NICE has recognised the benefits of EYLEA (aflibercept solution for injection) for the treatment of visual impairment due to diabetic macular oedema (DMO) according to a draft decision released 19 February.

However, Bayer is disappointed that a core group of patients diagnosed with early stage DMO (central retinal thickness <400 micrometres) would be denied treatment until their disease has progressed to a stage where permanent damage to the eye has already begun. Bayer is committed to working with NICE throughout the appraisal process to ensure all DMO patients have access to EYLEA when the decision is finalised; expected in June 2015.